ID   RPMI-2650
AC   CVCL_1664
SY   RPMI 2650; RPMI2650; R.P.M.I. #2650; Roswell Park Memorial Institute 2650
DR   BTO; BTO:0004205
DR   CLO; CLO_0008869
DR   CLO; CLO_0008876
DR   EFO; EFO_0006478
DR   CLDB; cl4174
DR   CLDB; cl4175
DR   CLDB; cl4176
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CCL-30
DR   BCRC; 60296
DR   BioSample; SAMN01821660
DR   BioSample; SAMN01821717
DR   BioSample; SAMN03473151
DR   cancercelllines; CVCL_1664
DR   Cell_Model_Passport; SIDM00809
DR   ChEMBL-Cells; CHEMBL3308780
DR   ChEMBL-Targets; CHEMBL1075566
DR   CLS; 300323
DR   Cosmic; 686978
DR   Cosmic; 909700
DR   Cosmic; 1006465
DR   Cosmic; 1017789
DR   Cosmic; 1041670
DR   Cosmic; 1339925
DR   Cosmic; 2043886
DR   Cosmic-CLP; 909700
DR   DepMap; ACH-001385
DR   DSMZ; ACC-287
DR   DSMZCellDive; ACC-287
DR   ECACC; 88031602
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 909700
DR   GEO; GSM960607
DR   GEO; GSM960608
DR   GEO; GSM960609
DR   GEO; GSM960610
DR   GEO; GSM960611
DR   GEO; GSM960612
DR   GEO; GSM960613
DR   GEO; GSM1374853
DR   GEO; GSM1374854
DR   GEO; GSM1670386
DR   IARC_TP53; 21290
DR   IGRhCellID; RPMI2650%20GSE9585
DR   IZSLER; BS TCL 59
DR   JCRB; JCRB9058
DR   KCLB; 10030
DR   LINCS_LDP; LCL-1881
DR   PharmacoDB; RPMI2650_1324_2019
DR   PubChem_Cell_line; CVCL_1664
DR   Wikidata; Q54951175
RX   DOI=10.1007/978-1-4757-1647-4_13;
RX   DOI=10.1007/BF02618370;
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=77569;
RX   PubMed=174085;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=1260760;
RX   PubMed=3518877;
RX   PubMed=5831238;
RX   PubMed=6277475;
RX   PubMed=14082866;
RX   PubMed=20215515;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=29348827;
RX   PubMed=30894373;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Population: Caucasian.
CC   Doubling time: ~40-50 hours (DSMZ=ACC-287).
CC   HLA typing: A*02,03; B*07,w22; C*w03,w06 (PubMed=77569).
CC   HLA typing: A*02:01,03:01; B*07:02,35:08; C*03:03,07:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 13575; BRD4 + HGNC; 29919; NUTM1; Name(s)=BRD4-NUTM1, BRD4-NUT; Note=BRD4 exon 15 fused to NUTM1 exon 2 (PubMed=25485619; PubMed=29348827).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.38%; Native American=0.9%; East Asian, North=1.71%; East Asian, South=0%; South Asian=0%; European, North=68.78%; European, South=28.23% (PubMed=30894373).
CC   Misspelling: CCL30; Note=Based on the ATCC catalog number.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC; CLS; Cosmic-CLP; DepMap; DSMZ; ECACC; JCRB; KCLB; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 9,11
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D18S51: 16
ST   D19S433: 14,16
ST   D21S11: 28,33.2
ST   D2S1338: 20,25
ST   D3S1358: 17
ST   D5S818: 12,13
ST   D7S820: 8,11
ST   D8S1179: 9,13
ST   FGA: 23,25
ST   Penta D: 9,10
ST   Penta E: 11,19
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C34447; Head and neck squamous cell carcinoma
DI   NCIt; C45716; NUT carcinoma
DI   ORDO; Orphanet_443167; NUT midline carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 41
//
RX   DOI=10.1007/978-1-4757-1647-4_13;
RA   Biedler J.L.;
RT   "Chromosome abnormalities in human tumor cells in culture.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975).
//
RX   DOI=10.1007/BF02618370;
RA   Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.;
RT   "The animal cell culture collection.";
RL   In Vitro 5:1-16(1970).
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
//
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
//
RX   PubMed=174085; DOI=10.1073/pnas.72.12.4971;
RA   Stiles C.D., Desmond W. Jr., Sato G.H., Saier M.H. Jr.;
RT   "Failure of human cells transformed by simian virus 40 to form tumors
RT   in athymic nude mice.";
RL   Proc. Natl. Acad. Sci. U.S.A. 72:4971-4975(1975).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1260760;
RA   Stiles C.D., Desmond W. Jr., Chuman L.M., Sato G.H., Saier M.H. Jr.;
RT   "Growth control of heterologous tissue culture cells in the
RT   congenitally athymic nude mouse.";
RL   Cancer Res. 36:1353-1360(1976).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=5831238; DOI=10.1016/0014-4827(65)90022-4;
RA   Moorhead P.S.;
RT   "Human tumor cell line with a quasi-diploid karyotype (RPMI 2650).";
RL   Exp. Cell Res. 39:190-196(1965).
//
RX   PubMed=6277475;
RA   Frampton R.J., Suva L.J., Eisman J.A., Findlay D.M., Moore G.E.,
RA   Moseley J.M., Martin T.J.;
RT   "Presence of 1,25-dihydroxyvitamin D3 receptors in established human
RT   cancer cell lines in culture.";
RL   Cancer Res. 42:1116-1119(1982).
//
RX   PubMed=14082866;
RA   Moore G.E., Mount D., Tara G., Schwartz N.;
RT   "Growth of human tumor cells in suspension cultures.";
RL   Cancer Res. 23:1735-1741(1963).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29348827; DOI=10.18632/oncotarget.22862;
RA   Stirnweiss A., Oommen J., Kotecha R.S., Kees U.R., Beesley A.H.;
RT   "Molecular-genetic profiling and high-throughput in vitro drug
RT   screening in NUT midline carcinoma-an aggressive and fatal disease.";
RL   Oncotarget 8:112313-112329(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//